AMRN
Amarin Corporation plc13.97
-0.17-1.2%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
290.47MP/E (TTM)
-Basic EPS (TTM)
-4.20Dividend Yield
0%Recent Filings
8-K
Amarin appoints new COO
Amarin Corporation appointed David Keenan, Ph.D., as Executive Vice President and Chief Operating Officer, effective October 17, 2025, expanding his prior role in technical operations and European leadership. With over 30 years in biopharma, including expertise in supply chain and M&A integration, Keenan steps up without compensation changes. This internal promotion signals streamlined operations amid Amarin's global challenges. No disruptions expected.
10-Q
Q2 FY2025 results
Amarin's Q2 revenue climbed 8% year-over-year to $72.7M, fueled by a $25M upfront from the Recordati Europe licensing deal, though U.S. product sales dipped 17% to $36.5M amid generic pressure and a lost PBM contract. Gross margin expanded to 52% from 48%, thanks to a richer international mix, but restructuring costs hit $22.8M as the firm slashed European commercial roles for $70M annual savings. Operating loss widened to $16.0M from $0.5M, with net loss at $14.1M or $(0.03) per share—anti-dilutive shares kept basic and diluted EPS aligned. Cash swelled to $298.7M debt-free, supporting operations. Restructuring sharpens focus. Generic erosion persists.
8-K
Amarin partners with Recordati
Amarin inked an exclusive license deal with Recordati in June 2025 to commercialize VAZKEPA across 59 European countries, handing off the reins to accelerate adoption while pocketing upfront cash that boosted Q2 net revenue to $72.7 million, up 8% from last year. The move triggered a global restructuring, slashing operating expenses by $70 million over the next year through axing European commercial roles. Cash sits at $298.7 million, debt-free. Restructuring risks linger.
8-K
Amarin licenses VAZKEPA to Recordati
Amarin Corporation inked an exclusive 15-year license deal on June 20, 2025, with Recordati for VAZKEPA commercialization in 59 European countries, netting $25 million upfront and up to $150 million in milestones, plus royalties on net sales. This partnership, announced June 24, triggered a global restructuring slashing Europe commercialization costs for $70 million annual savings, substantially complete by June 30, 2026, though incurring $30-37 million in Q2 2025 charges. Restructuring bolsters cash flow amid U.S. VASCEPA revenue and rest-of-world partnerships.
8-K
Amarin AGM: Key proposal rejected
Amarin Corporation plc held its Annual General Meeting on May 13, 2025, where shareholders re-elected all directors and approved most proposals, including auditor appointment and general share allotment authority. Yet Proposal 12 failed, blocking the board from issuing 10% of shares without pre-emption rights despite ISS and Glass Lewis support. This forces case-by-case opt-outs for issuances, complicating director equity awards worth $175,000 annually. The board will pivot to cash compensation, straining the cash position.
IPO
Website
Employees
Sector
Industry
AMGN
Amgen Inc.
326.74+1.43
AMPH
Amphastar Pharmaceuticals, Inc.
25.61-0.70
AMRX
Amneal Pharmaceuticals, Inc.
12.17-0.29
AZN
Astrazeneca PLC
91.35-0.21
BIOE
Bio Essence Corp.
0.05+0.00
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
MRMD
MariMed Inc.
0.12+0.01
NVO
Novo Nordisk A/S
48.96-1.41
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
VTRS
Viatris Inc.
11.46-0.20